Familial Cancer

, Volume 11, Issue 3, pp 441–447 | Cite as

Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry

  • Mala Pande
  • Chongjuan Wei
  • Jinyun Chen
  • Christopher I. Amos
  • Patrick M. Lynch
  • Karen H. Lu
  • Laura A. Lucio
  • Stephanie G. Boyd-Rogers
  • Sarah A. Bannon
  • Maureen E. Mork
  • Marsha L. Frazier
Original Article


The spectrum of cancers seen in a hospital based Lynch syndrome registry of mismatch repair gene mutation carriers was examined to determine the distribution of cancers and examine excess cancer risk. Overall there were 504 cancers recorded in 368 mutation carriers from 176 families. These included 236 (46.8 %) colorectal and 268 (53.2 %) extracolonic cancers. MLH1 mutation carriers had a higher frequency of colorectal cancers whereas MSH2, MSH6 and PMS2 mutation carriers had more extracolonic cancers although these differences were not statistically significant. Men had fewer extracolonic cancers than colorectal (45.3 vs. 54.7 %), whereas women had more extracolonic than colorectal cancers (59.0 vs. 41.0 %). The mean age at diagnosis overall for extracolonic cancers was older than for colorectal, 49.1 versus 44.8 years (P ≤ 0.001). As expected, the index cancer was colorectal in 58.1 % of patients and among the extracolonic index cancers, endometrial was the most common (13.8 %). A significant number of non-Lynch syndrome index cancers were recorded including breast (n = 5) prostate (n = 3), thyroid (n = 3), cervix (n = 3), melanoma (n = 3), and 1 case each of thymoma, sinus cavity, and adenocarcinoma of the lung. However, standardized incidence ratios calculated to assess excess cancer risk showed that only those cancers known to be associated with Lynch syndrome were significant in our sample. We found that Lynch syndrome patients can often present with cancers that are not considered part of Lynch syndrome. This has clinical relevance both for diagnosis of Lynch syndrome and surveillance for cancers of different sites during follow-up of these patients.


Lynch syndrome cancers Colorectal Extracolonic Index cancer 



This research was supported in part by the National Institutes of Health through MD Anderson’s Cancer Center Support Grant (CA016672) which supports the Biospecimen and Extraction Resource and the Human Pedigree Analysis Resource service cores; and research grant 5R01CA070759-11.


  1. 1.
    Geary J, Sasieni P, Houlston R, Izatt L, Eeles R, Payne SJ, Fisher S, Hodgson SV (2008) Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 7:163–172PubMedCrossRefGoogle Scholar
  2. 2.
    Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X, Xicola RM, Rodriguez-Moranta F, Paya A, Jover R, Bessa X (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986–1994PubMedCrossRefGoogle Scholar
  3. 3.
    Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, Harkonen N, Julkunen R, Kangas E, Ojala S, Tulikoura J, Valkamo E, Jarvinen H, Mecklin JP, Aaltonen LA, de la Chapelle A (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18:2193–2200PubMedGoogle Scholar
  4. 4.
    Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, Comeras I, de la Chapelle A (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783–5788Google Scholar
  5. 5.
    Lynch HT, Ens J, Lynch JF, Watson P (1988) Tumor variation in three extended Lynch syndrome II kindreds. Am J Gastroenterol 83:741–747PubMedGoogle Scholar
  6. 6.
    Lynch HT, Lynch JF (1993) The Lynch syndromes. Curr Opin Oncol 5:687–696PubMedCrossRefGoogle Scholar
  7. 7.
    Lin KM, Shashidharan M, Ternent CA, Thorson AG, Blatchford GJ, Christensen MA, Lanspa SJ, Lemon SJ, Watson P, Lynch HT (1998) Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum 41:428–433PubMedCrossRefGoogle Scholar
  8. 8.
    da Silva FC, de Oliveira LP, Santos EM, Nakagawa WT, Aguiar JS, Valentin MD, Rossi BM, de Oliveira FF (2010) Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry. Fam Cancer 9:563–570PubMedCrossRefGoogle Scholar
  9. 9.
    Watson P, Riley B (2005) The tumor spectrum in the Lynch syndrome. Fam Cancer 4:245–248PubMedCrossRefGoogle Scholar
  10. 10.
    Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116:1453–1456PubMedCrossRefGoogle Scholar
  11. 11.
    Lynch HT, Fusaro RM, Roberts L, Voorhees GJ, Lynch JF (1985) Muir-Torre syndrome in several members of a family with a variant of the Cancer Family Syndrome. Br J Dermatol 113:295–301PubMedCrossRefGoogle Scholar
  12. 12.
    Schwartz RA, Torre DP (1995) The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol 33:90–104PubMedCrossRefGoogle Scholar
  13. 13.
    Giardiello FM (1997) Genetic testing in hereditary colorectal cancer. JAMA 278:1278–1281PubMedCrossRefGoogle Scholar
  14. 14.
    Peltomaki P, Vasen HF (1997) Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International collaborative group on hereditary nonpolyposis colorectal cancer. Gastroenterology 113:1146–1158PubMedCrossRefGoogle Scholar
  15. 15.
    Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri RJ, Boland CR (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104:1535–1549PubMedGoogle Scholar
  16. 16.
    Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19:4074–4080PubMedGoogle Scholar
  17. 17.
    Bai YQ, Akiyama Y, Nagasaki H, Lu SL, Arai T, Morisaki T, Kitamura M, Muto A, Nagashima M, Nomizu T, Iwama T, Itoh H, Baba S, Iwai T, Yuasa Y (1999) Predominant germ-line mutation of the hMSH2 gene in Japanese hereditary non-polyposis colorectal cancer kindreds. Int J Cancer 82:512–515PubMedCrossRefGoogle Scholar
  18. 18.
    Kim JC, Kim HC, Roh SA, Koo KH, Lee DH, Yu CS, Lee JH, Kim TW, Lee HL, Beck NE, Bodmer WF (2001) hMLH1 and hMSH2 mutations in families with familial clustering of gastric cancer and hereditary non-polyposis colorectal cancer. Cancer Detect Prev 25:503–510PubMedGoogle Scholar
  19. 19.
    Rossi BM, Lopes A, Oliveira FF, Nakagawa WT, Napoli Ferreira CC, Casali Da Rocha JC, Simpson CC, Simpson AJ (2002) hMLH1 and hMSH2 gene mutation in Brazilian families with suspected hereditary nonpolyposis colorectal cancer. Ann Surg Oncol 9:555–561PubMedGoogle Scholar
  20. 20.
    Liu M, Scheurer ME, Bondy ML, Strom SS, Amos CI, Etzel CJ (2007) Extension of the cohort analysis for genetic epidemiology program to assess excess risk of cancer. American Statistical Association. Proceeding of the 2007 Joint Statistical Meeting, pp 2546–2550Google Scholar
  21. 21.
    Bandipalliam P, Garber J, Kolodner RD, Syngal S (2004) Clinical presentation correlates with the type of mismatch repair gene involved in hereditary nonpolyposis colon cancer. Gastroenterology 126:936–937PubMedCrossRefGoogle Scholar
  22. 22.
    Jensen UB, Sunde L, Timshel S, Halvarsson B, Nissen A, Bernstein I, Nilbert M (2010) Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat 120:777–782PubMedCrossRefGoogle Scholar
  23. 23.
    Walsh MD, Buchanan DD, Cummings MC, Pearson SA, Arnold ST, Clendenning M, Walters R, McKeone DM, Spurdle AB, Hopper JL, Jenkins MA, Phillips KD, Suthers GK, George J, Goldblatt J, Muir A, Tucker K, Pelzer E, Gattas MR, Woodall S, Parry S, Macrae FA, Haile RW, Baron JA, Potter JD, Le ML, Bapat B, Thibodeau SN, Lindor NM, McGuckin MA, Young JP (2010) Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res 16:2214–2224PubMedCrossRefGoogle Scholar
  24. 24.
    Muller A, Edmonston TB, Corao DA, Rose DG, Palazzo JP, Becker H, Fry RD, Rueschoff J, Fishel R (2002) Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res 62:1014–1019 Google Scholar
  25. 25.
    de Leeuw WJ, van PM, Tollenaar RA, Cornelisse CJ, Vasen HF, Morreau H (2003) Correspondence re: A. Muller et al., Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res 63:1148–1149Google Scholar
  26. 26.
    Vasen HF, Morreau H, Nortier JW (2001) Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer? Am J Hum Genet 68:1533–1535Google Scholar
  27. 27.
    Bauer CM, Ray AM, Halstead-Nussloch BA, Dekker RG, Raymond VM, Gruber SB, Cooney KA (2011) Hereditary prostate cancer as a feature of Lynch syndrome. Fam Cancer 10:37–42Google Scholar
  28. 28.
    Grindedal EM, Moller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landro SM, Clark N, Kvale R, Shanley S, Maehle L (2009) Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 18:2460–2467Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Mala Pande
    • 1
  • Chongjuan Wei
    • 1
  • Jinyun Chen
    • 1
  • Christopher I. Amos
    • 2
  • Patrick M. Lynch
    • 3
  • Karen H. Lu
    • 4
  • Laura A. Lucio
    • 1
  • Stephanie G. Boyd-Rogers
    • 4
  • Sarah A. Bannon
    • 5
  • Maureen E. Mork
    • 3
  • Marsha L. Frazier
    • 1
  1. 1.Department of EpidemiologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of GeneticsThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of Gastroenterology, Hepatology and NutritionThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Department of Gynecologic Oncology and Reproductive MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA
  5. 5.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations